



INSPIRED BY
OPPORTUNITY.
DRIVEN BY
KNOWLEDGE.

INSIGHT Volume 3, August - 2019

US FDA HAS APPROVED ABBVIE'S NEW BLOCKBUSTER RINVOQ TO TREAT RHEUMATOID ARTHRITIS (RA)

Based on results of a [phase III clinical trial](#) covering 4,400 patients across five studies, [Rinvoq](#) demonstrated greater efficacy than current therapies available in the market. This makes Rinvoq the first [Janus Kinase \(JAK\) inhibitor](#) class drug to show a superior endpoint with multiple criteria in a head-to-head comparison with other therapies.

The drug will be available in the US market this month and is [under review](#) by other regulators including the European Medicines Agency and Health Canada. AbbVie has [priced](#) the drug at USD 59,000 per year, and expects USD 2.2 Billion in sales per year by 2023.

RA is an [autoimmune disease](#) that affects about [1% of the global population](#). In RA, the immune system attacks joints, causing inflammation and thickening, resulting in swelling and pain.

APPLE, ELI LILY AND EVIDATION HEALTH TEAM UP TO DETECT ALZHEIMER'S DISEASE DEMENTIA WITH IPHONES AND IWATCHES

A [study](#) conducted by the three companies on 113 participants over the age of 60 in a 12-week time period has yielded promising initial [results](#). A combination of devices and Apple's Beddit sleep monitor has been successful in isolating [digital biomarkers](#) that distinguish a symptomatic patient from a healthy volunteer. Eli Lilly's Chief Digital Officer, Divakar Ramakrishnan, hopes this research will enable early screening and detection of chronic neurodegenerative conditions.

Alzheimer's disease is a [progressive neurodegenerative disorder](#) leading to dementia, marked by a decline in thinking, behavior and social skills, and ultimately to death. Alzheimer's disease and other dementias affect [40-50 million](#) people globally.

PFIZER'S GENERICS DIVISION, UPJOHN, TO BE SPUN OFF AND MERGED WITH MYLAN TO CREATE A NEW USD 20 BN COMPANY

America's largest drug maker, Pfizer, [announced](#) an all stock deal to create a new global pharmaceutical company, with Pfizer shareholders owning 57% of the new entity, and Mylan shareholders 43%.

The move, unanimously approved by the Boards of Directors of both Pfizer and Mylan, will create a USD 19-20 Billion company with sales in over 165 countries that will have former blockbusters like Lipitor and Viagra in its portfolio. Mylan's Chairman, Robert J. Coury, will be Executive Chairman; Upjohn's Group President, Michael Goettler, will serve as Chief Executive Officer (CEO); and Mylan's President, Rajiv Malik, will be President of the new company.

This yet-to-be-named company will focus on a [global approach](#) to generic and branded off-patent drugs. The established competence of both Pfizer and Mylan, and their expressed hopes to expand their reach in the China market through this new company promises a new growth engine in the face of extensive pressure on pharmaceutical pricing in the US market.

TAKE Solutions has successfully delivered 1000+ Bioavailability & Bioequivalence Studies to enable Generics companies to bring their drugs to market quickly and effectively

TAKE has developed over 250 bioanalytical methods to quantify the amount of drug available in biological samples. Our state-of-the-art, GLP, 21 CFR Part 11 compliant lab in Bangalore is equipped with LC-MS/MS (Sciex API 6500, Waters Xevo TQ-S, Thermo Ultra & Thermo Discovery Max) including UPLC, and ICP-MS (Agilent 7700x in Class 10000 clean air lab facility) machines. Our team of experts can develop and validate new bioanalytical methods within 4 weeks to enable Generics companies be first to market.



ABOUT TAKE SOLUTIONS

TAKE Solutions delivers domain-intensive services in Life Sciences and Supply Chain Management.

In the fast-growing Life Sciences space, TAKE offers clients a unique combination of full-service Clinical, Regulatory and Safety services backed by unique technology expertise. Our range of services span from clinical trials to regulatory submissions to post-marketing safety, all backed by insights derived through proprietary industry networks forums. With a team of leading Life Sciences experts, best-in-class systems and processes, and bespoke, industry-specific technology and analytics, TAKE delivers successful outcomes for clients. Our global roster of clients includes large and small innovator biopharmaceutical companies as well as generics manufacturers.

With operations spread across North America, Europe, Asia, and South America, TAKE is a Public Company, listed in India on the Bombay Stock Exchange and the National Stock Exchange. Led by a team of industry stalwarts and domain experts, TAKE has been growing steadily with FY19 revenues touching INR 20,390 Mn (USD 292 Mn).

For more details, please visit www.takesolutions.com.